Publications by authors named "E Pezalla"
Article Synopsis
- * A majority (70.6%) recognized simplicity and convenience as the main benefits of OBDS, while 88.2% believed it could address unmet needs like reducing IV costs and improving patient compliance.
- * Most payers (88.2%) indicated willingness to cover drugs using OBDS, and 82.4% noted the potential for a price premium compared to standard subcutaneous (SC) drugs, with half estimating a 5-20% increase in price.
Article Synopsis
- Existing healthcare systems struggle with limited resources, prompting the development of a user-friendly on-body delivery system (OBDS) for administering large-volume subcutaneous drugs at home or in clinical settings.
- Research evaluated the economic impact of this system through literature reviews and interviews with US payers, revealing that OBDS offers potential cost savings due to reduced healthcare resource use and improved patient compliance.
- Payers noted that features like the hidden needle and ease-of-use enhance patient experience, making OBDS a viable option that could justify a higher price than traditional administration methods.
Overview of alopecia areata for managed care and payer stakeholders in the United States.
J Manag Care Spec Pharm
July 2023
Article Synopsis
- - Alopecia areata (AA) is an autoimmune condition that leads to non-scarring hair loss and significantly affects patients' quality of life, often leading to economic burdens and increased prevalence of psychiatric conditions and other health issues.
- - Current treatment options mainly include corticosteroids and emerging therapies like JAK inhibitors, which specifically target the underlying immune response, though more reliable data on treatment effectiveness is still needed.
- - A new tool called the Alopecia Areata Severity Scale has been developed to evaluate the severity of the disease, aiming to provide a more comprehensive approach to managing AA and informing healthcare decisions.
Healthcare decision-makers face difficult decisions regarding COVID-19 booster selection given limited budgets and the need to maximize healthcare gain. A constrained optimization (CO) model was developed to identify booster allocation strategies that minimize bed-days by varying the proportion of the eligible population receiving different boosters, stratified by age, and given limited healthcare expenditure. Three booster options were included: B, costing US $1 per dose, B, costing US $2, and no booster (NB), costing US $0.
View Article and Find Full Text PDFHealth insurance coverage and switching among people with hemophilia A in the United States.
J Manag Care Spec Pharm
February 2022
Article Synopsis
- Hemophilia A (HA) poses significant economic challenges due to costs related to ongoing treatment, monitoring, and managing associated health issues; gene therapies could help reduce these costs in the long term but face coverage hurdles from the fragmented US insurance system.
- A study analyzed data from adults with severe hemophilia A to understand insurance coverage, revealing that over half had commercial insurance and most did not frequently switch coverage types.
- Among those with commercial insurance, a high percentage maintained the same provider over a lengthy follow-up period, indicating stability in coverage despite the potential for insurance switching.